Table 1. Clinical and demographic characteristics of study participants.
| Participant Characteristics | MDR-TB HIV positive (n = 64) | MDR-TB HIV negative (n = 21) | DS-TB (n = 89) | LTBI (n = 20) | Controls without Mtb infection (n = 37) |
|---|---|---|---|---|---|
| Female sex, n (%) | 42 (66) | 11 (52) | 31 (35) | 9 (45) | 31 (84) |
| Age, years (median [IQR]) | 35 (29–41) | 28 (20–48) | 31 (24–43) | 39 (28–44) | 51 (41–56) |
| CD4, cells/mm3 (median [IQR]) |
229 (138–400) | N/A | N/A | N/A | N/A |
| HIV Viral Load, copies/mL (median [IQR]) |
122 (<40–14,850) | N/A | N/A | N/A | N/A |
| Receiving anti-retroviral therapy at enrollment n (%) | 50 (78) | N/A | N/A | N/A | N/A |
| TB disease history, n (%) No TB history Yes, completed treatment Yes, failed treatment |
21 (33) 31 (48) 12 (19) |
9 (43) 6 (29) 6 (29) |
89 (100) |
N/A | N/A |
| +AFB smear at first study visit, n (%)* | 28 (56) | 8 (50) | 67 (75) | N/A | N/A |
| +Sputum culture at diagnosis, n (%) | 64 (100) | 21 (100) | 89 (100) | N/A | N/A |
| +Sputum culture at first study visit, n (%)** | 56 (79) | 16 (80) | 76 (85) | N/A | N/A |
| Time to sputum culture conversion, days (median [IQR]) § | 81 (51–90) | 57 (53–80) | 28 (22–47) | N/A | N/A |
Multidrug resistant (MDR); Drug susceptible (DS)
*AFB sputum smear results were not available for 19 MDR-TB participants (22.4%)
**AFB sputum culture results were not available for 14 MDR-TB participants (16.5%)
§Data on sputum culture conversion was missing for 7 MDR-TB participants (12.5%) with a positive sputum culture at baseline